Czaplinska D, Turczyk L, Grudowska A, Mieszkowska M, Lipinska A, Skladanowski A, et al. Phosphorylation of RSK2 at Tyr529 by FGFR2-p38 enhances human mammary epithelial cells migration. Biochim Biophys Acta. 2014;1843:2461-70 pubmed publisher

Boichuk S, Dunaev P, Skripova V, Galembikova A, Bikinieva F, Shagimardanova E, et al. Unraveling the Mechanisms of Sensitivity to Anti-FGF Therapies in Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST) Lacking Secondary KIT Mutations. Cancers (Basel). 2023;15: pubmed publisher

Zarczynska I, Gorska Arcisz M, Cortez A, Kujawa K, Wilk A, Skladanowski A, et al. p38 Mediates Resistance to FGFR Inhibition in Non-Small Cell Lung Cancer. Cells. 2021;10: pubmed publisher

Kitowska K, Gorska Arcisz M, Antoun D, Zarczynska I, Czaplinska D, Szczepaniak A, et al. MET-Pyk2 Axis Mediates Acquired Resistance to FGFR Inhibition in Cancer Cells. Front Oncol. 2021;11:633410 pubmed publisher

Valencia T, Joseph A, Kachroo N, Darby S, Meakin S, Gnanapragasam V. Role and expression of FRS2 and FRS3 in prostate cancer. BMC Cancer. 2011;11:484 pubmed publisher

Dutt A, Ramos A, Hammerman P, Mermel C, Cho J, Sharifnia T, et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS ONE. 2011;6:e20351 pubmed publisher

Dutt A, Salvesen H, Chen T, Ramos A, Onofrio R, Hatton C, et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A. 2008;105:8713-7 pubmed publisher